



# ESMO Preceptorship on Immuno-Oncology

## PROGRAMME

**ESMO PRECEPTORSHIP**

**ZURICH SWITZERLAND  
29-30 SEPTEMBER 2023**

**Co-Chairs**

Alessandra Curioni-Fontecedro, Switzerland  
James Larkin, United Kingdom

# ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY

From the essentials of tumour immunology to clinical application

**Zurich, Switzerland**  
**29-30 September 2023**

---

**CO-CHAIRS** Alessandra Curioni-Fontecedro, Switzerland  
James Larkin, United Kingdom

**SPEAKERS** Angela Lamarca, Spain  
Antonio Marra, Italy  
Michel Obeid, Switzerland  
Steve Pascolo, Switzerland  
Solange Peters, Switzerland  
David James Pinato, United Kingdom  
Tom Seijkens, Netherlands

---

## LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their applications in cancer medicine
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

---

## ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano, Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Friday, 29 September 2023

<b>09:00-09:10</b> 10'	<b>Welcome and Introduction</b>	<b>Alessandra Curioni-Fontecedro, CH</b> <b>James Larkin, UK</b>
<b>09:10-11:50</b> 160'	<b>SESSION 1</b> <b>Essentials of tumour immunology</b>	<b>Chair:</b> <b>James Larkin, UK</b>
30'	Basic tumour immunology for oncologists	Michel Obeid, CH
20'	Adjuvant vs neoadjuvant	Solange Peters, CH
15'	Q&A	All
<b>10:15-10:45</b>	<b>Coffee break</b>	
30'	Mechanisms of immune resistance	Alessandra Curioni-Fontecedro, CH
20'	Biomarkers for immunotherapy	David James Pinato, UK
15'	Q&A	All
<b>11:50-12:50</b>	<b>Lunch</b>	
<b>12:50-13:50</b> 60'	<b>SESSION 2</b> <b>Clinical development– Part I</b>	<b>Chair:</b> <b>James Larkin, UK</b>
25'	Immunotherapy for SCLC and mesothelioma	Alessandra Curioni-Fontecedro, CH
25'	Immunotherapy for NSCLC	Solange Peters, CH
10'	Q&A	All
<b>13:50-14:50</b> 60'	<b>SESSION 3</b> <b>Clinical development – Part II</b>	<b>Chair:</b> <b>James Larkin, UK</b>
25'	Immunotherapy for breast cancer	Antonio Marra, IT
25'	Immunotherapy for gynaecological malignancies	Antonio Marra, IT
10'	Q&A	All
<b>14:50-15:20</b>	<b>Coffee break</b>	
<b>15:20-16:20</b> 60'	<b>SESSION 4</b> <b>Clinical development – Part III</b>	<b>Chair:</b> <b>Alessandra Curioni-Fontecedro, CH</b>
25'	Immunotherapy for melanoma	James Larkin, UK
25'	Immunotherapy for gastro-intestinal cancers	David James Pinato, UK
10'	Q&A	All
<b>16:20-17:20</b> 60'	<b>SESSION 5</b> <b>Essentials in immunotherapy – Part I</b>	<b>Chair:</b> <b>Alessandra Curioni-Fontecedro, CH</b>
25'	Developments in adoptive T-cell transfer	Tom Seijkens, NL
25'	Developments in immune checkpoint inhibition	Tom Seijkens, NL
10'	Q&A	All
<b>19:00</b>	<b>Dinner</b>	

**Saturday, 30 September 2023**

<b>09:00-10:00 60'</b>	<b>SESSION 6 Clinical development – Part IV</b>	<b>Chair: Alessandra Curioni-Fontecedro, CH</b>
25'	Immunotherapy for renal cancer	James Larkin, UK
25'	Immunotherapy for liver and biliary cancer	Angela Lamarca, ES
10'	Q&A	All
<b>10:00-10:35 35'</b>	<b>SESSION 7 Essentials in immunotherapy – Part II</b>	<b>Chair: James Larkin, UK</b>
25'	Anticancer RNAs: Vaccines and therapies	Steve Pascolo, CH
10'	Q&A	All
10:35-11:00	Coffee break	
<b>11:00-12:00 60'</b>	<b>SESSION 8 Immune toxicity and management</b>	<b>Chair: James Larkin, UK</b>
45'	IrAEs and management of toxicities	Michel Obeid, CH
15'	Q&A	All
<b>12:00-13:00 60'</b>	<b>SESSION 9 Audience cases</b>	<b>Chair: Alessandra Curioni-Fontecedro, CH</b>
60'	Participants clinical case discussion (6x10')	Faculty
<b>13:00-13:10 10'</b>	<b>General discussion &amp; Closure</b>	<b>Alessandra Curioni-Fontecedro, CH James Larkin, UK</b>
13:10-14:10	Lunch	

**Note:** Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion